← Back to Search

GLP-1 Receptor Agonist

Individualized Obesity Pharmacotherapy

Phase 3
Waitlist Available
Led By Andres J Acosta
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12 weeks
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing if choosing weight loss medications based on individual body traits works better than picking them randomly. Participants with obesity will either get a medication chosen for them or one picked without considering their traits. The study will track their progress to see which method is more effective.

Eligible Conditions
  • Obesity

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Total Body Weight
Secondary study objectives
Percentage of Responders

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention groupExperimental Treatment3 Interventions
Phenotype-guided pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine plus Exercise
Group II: Control GroupActive Control4 Interventions
Randomly assigned pharmacotherapy, which includes Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion or Phentermine
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liraglutide
2013
Completed Phase 4
~2680
Phentermine-Topiramate
2017
Completed Phase 3
~200
Naltrexone/bupropion
2017
Completed Phase 3
~200

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,353 Previous Clinical Trials
3,060,830 Total Patients Enrolled
87 Trials studying Obesity
8,941 Patients Enrolled for Obesity
Andres J AcostaPrincipal InvestigatorMayo Clinic
~24 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top